NEW YORK (GenomeWeb News) — Shares in Cepheid were up 6 percent to a new 52-week high of $12.47 in mid-afternoon trading today after the company this morning said the US Food and Drug Administration cleared one of its tests.
 
As GenomeWeb Daily News reported this morning, the company’s PCR-based Xpert MRSA test is designed to detect drug-resistant Staphylococcus aureus infections.   
  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.